Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
BeOne Medicines Ltd ADR (NASDAQ: ONC) closed the day trading at $332.71 down -4.32% from the previous closing price of $347.72. In other words, the price has decreased by -$4.32 from its previous closing price. On the day, 0.64 million shares were traded. ONC stock price reached its highest trading level at $356.2 during the session, while it also had its lowest trading level at $322.4135.
Ratios:
For a better understanding of ONC, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 62.04. For the most recent quarter (mrq), Quick Ratio is recorded 2.17 and its Current Ratio is at 2.39. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.25.
On September 18, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $385.
On April 07, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $312.RBC Capital Mkts initiated its Outperform rating on April 07, 2025, with a $312 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’25 when Wu Xiaobin sold 3,991 shares for $380.43 per share. The transaction valued at 1,518,303 led to the insider holds 0 shares of the business.
XIAOBIN WU bought 3,991 shares of ONC for $1,518,303 on Nov 17 ’25. On Nov 12 ’25, another insider, Wu Xiaobin, who serves as the President and COO of the company, sold 10,000 shares for $356.02 each. As a result, the insider received 3,560,161 and left with 6,009 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ONC now has a Market Capitalization of 36817002496 and an Enterprise Value of 475604189184. As of this moment, BeOne’s Price-to-Earnings (P/E) ratio for their current fiscal year is 640.07, and their Forward P/E ratio for the next fiscal year is 51.46. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.80 while its Price-to-Book (P/B) ratio in mrq is 8.91. Its current Enterprise Value per Revenue stands at 95.643 whereas that against EBITDA is 1449.257.
Stock Price History:
The Beta on a monthly basis for ONC is 0.41, which has changed by 0.8100047 over the last 52 weeks, in comparison to a change of 0.09654534 over the same period for the S&P500. Over the past 52 weeks, ONC has reached a high of $385.22, while it has fallen to a 52-week low of $170.99. The 50-Day Moving Average of the stock is 0.12%, while the 200-Day Moving Average is calculated to be 17.98%.
Shares Statistics:
Over the past 3-months, ONC traded about 278.88K shares per day on average, while over the past 10 days, ONC traded about 342650 shares per day. A total of 101.77M shares are outstanding, with a floating share count of 101.28M. Insiders hold about 0.46% of the company’s shares, while institutions hold 32.24% stake in the company. Shares short for ONC as of 1761868800 were 1566239 with a Short Ratio of 5.62, compared to 1759190400 on 1324289. Therefore, it implies a Short% of Shares Outstanding of 1566239 and a Short% of Float of 2.01.
Earnings Estimates
The market rating of BeOne Medicines Ltd ADR (ONC) is currently shaped by the ongoing analysis conducted by 10.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.51, with high estimates of $1.03 and low estimates of $0.25.
Analysts are recommending an EPS of between $4.29 and $2.45 for the fiscal current year, implying an average EPS of $3.41. EPS for the following year is $6.37, with 16.0 analysts recommending between $9.41 and $1.03.
Revenue Estimates
11 analysts predict $1.46B in revenue for. The current quarter. It ranges from a high estimate of $1.52B to a low estimate of $1.42B. As of. The current estimate, BeOne Medicines Ltd ADR’s year-ago sales were $1.13BFor the next quarter, 11 analysts are estimating revenue of $1.41B. There is a high estimate of $1.43B for the next quarter, whereas the lowest estimate is $1.36B.
A total of 31 analysts have provided revenue estimates for ONC’s current fiscal year. The highest revenue estimate was $5.44B, while the lowest revenue estimate was $5.12B, resulting in an average revenue estimate of $5.28B. In the same quarter a year ago, actual revenue was $3.81BBased on 33 analysts’ estimates, the company’s revenue will be $6.39B in the next fiscal year. The high estimate is $7B and the low estimate is $5.72B.
